ImmuneBridge

ImmuneBridge is developing the next generation of allogeneic cell therapies, starting with NK cell-based immunotherapies, to make curative cancer treatments accessible to all. ImmuneBridge's proprietary expansion technology amplifies immune stem cells derived from umbilical cord blood while maintaining full immune pluripotency, creating a consistent and abundant source of cells for immunotherapy. ImmuneBridge's scientific approach leverages this expansion technology along with the unique advantages of umbilical cord blood to enable robust targeting of the most potent cancer-causing cells.